

**S2 Table.** EORTC scores after concurrent temozolomide or radiotherapy cycle 1

Dimension	CCRT with TMZ + TMZ 6cycles (n=38)	RT only (n=39)	p-value <sup>a)</sup>
<b>EORTC QLQ-C30</b>			
<b>Global health status/QoL</b>			
Global health status/QoL	50.0 (0.0-100.0)	66.7 (16.7-100.0)	0.330
<b>Functional scales</b>			
Physical functioning	80.0 (20.0-100.0)	80.0 (20.0-100.0)	1.000
Role functioning	83.3 (0.0-100.0)	83.3 (16.7-100.0)	0.983
Emotional functioning	75.0 (25.0-100.0)	75.0 (41.7-100.0)	0.318
Cognitive functioning	83.3 (0.0-100.0)	83.3 (33.3-100.0)	0.334
Social functioning	66.7 (33.3-100.0)	66.7 (0.0-100.0)	0.410
<b>Symptom scales</b>			
Fatigue	22.2 (0.0-88.9)	22.2 (0.0-66.7)	0.760
Nausea and vomiting	0.0 (0.0-66.7)	0.0 (0.0-33.3)	0.518
Pain	16.7 (0.0-83.3)	16.7 (0.0-50.0)	0.865
Dyspnea	0.0 (0.0-66.7)	0.0 (0.0-66.7)	0.507
Insomnia	0.0 (0.0-66.7)	0.0 (0.0-100.0)	0.896
Appetite loss	0.0 (0.0-100.0)	0.0 (0.0-100.0)	0.995
Constipation	0.0 (0.0-66.7)	0.0 (0.0-100.0)	0.823
Diarrhea	0.0 (0.0-66.7)	0.0 (0.0-66.7)	0.956
Financial difficulties	16.7 (0.0-100.0)	33.3 (0.0-100.0)	0.643
<b>EORTC QLQ-BN20</b>			
Future uncertainty	20.8 (0.0-91.7)	25.0 (0.0-91.7)	0.113
Visual disorder	0.0 (0.0-100.0)	5.6 (0.0-66.7)	0.527
Motor dysfunction	22.2 (0.0-100.0)	11.1 (0.0-66.7)	0.126
Communication deficit	11.1 (0.0-88.9)	0.0 (0.0-88.9)	0.280
Headaches	33.3 (0.0-100.0)	16.7 (0-66.7)	0.656
Seizures	0.0 (0.0-66.7)	0.0 (0.0-33.3)	0.165
Drowsiness	33.3 (0.0-100.0)	33.3 (0.0-100.0)	0.222
Itchy skin	0.0 (0.0-66.7)	0.0 (0.0-66.7)	0.765
Hair loss	0.0 (0.0-66.7)	0.0 (0.0-66.7)	0.364
Weakness of legs	16.7 (0.0-100)	33.3 (0.0-66.7)	0.869
Bladder control	0.0 (0.0-66.7)	0.0 (0.0-66.7)	0.603

Values are presented as median (min-max). CCRT, concurrent chemoradiotherapy; EORTC, European Organization for Research and Treatment of Cancer; QLQ-BN20, 20-item EORTC QLQ-Brain Neoplasm; QLQ-C30, Quality of Life Questionnaire 30; QoL, quality of life; RT, radiotherapy; TMZ, temozolomide. <sup>a)</sup>Wilcoxon rank sum test.